Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash & Equivalents (2016 - 2025)

Iradimed (IRMD) has disclosed Cash & Equivalents for 13 consecutive years, with $51.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 2.06% to $51.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.2 million through Dec 2025, down 2.06% year-over-year, with the annual reading at $51.2 million for FY2025, 2.06% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $51.2 million at Iradimed, down from $56.5 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $62.0 million in Q4 2021, with the low at $42.8 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $51.8 million, with a median of $51.4 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents grew 23.83% in 2021, then decreased 15.91% in 2023.
  • Over 5 years, Cash & Equivalents stood at $62.0 million in 2021, then dropped by 6.51% to $58.0 million in 2022, then dropped by 14.15% to $49.8 million in 2023, then grew by 4.97% to $52.2 million in 2024, then fell by 2.06% to $51.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $51.2 million, $56.5 million, and $53.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.